MYUNGMOON Pharm co.,Ltd (017180.KS)
KRW 1860.0
(-0.59%)
KRW 1860.0
(-0.59%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 963.76 Million KRW | -85.02% |
| 2022 | 6.43 Billion KRW | 209.4% |
| 2021 | -5.88 Billion KRW | 79.7% |
| 2020 | -28.96 Billion KRW | -102.63% |
| 2019 | -14.29 Billion KRW | -389.54% |
| 2018 | 4.93 Billion KRW | -33.94% |
| 2017 | 7.47 Billion KRW | -25.7% |
| 2016 | 10.05 Billion KRW | 507.15% |
| 2015 | -2.47 Billion KRW | -166.3% |
| 2014 | 3.72 Billion KRW | -9.24% |
| 2013 | 4.1 Billion KRW | 210.22% |
| 2012 | -3.72 Billion KRW | -134.61% |
| 2011 | 10.76 Billion KRW | 17.78% |
| 2010 | 9.13 Billion KRW | 35.04% |
| 2009 | 6.76 Billion KRW | -14.11% |
| 2008 | 7.87 Billion KRW | -19.38% |
| 2007 | 9.77 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -941.27 Million KRW | 58.66% |
| 2024 Q2 | -671.25 Million KRW | 28.69% |
| 2023 Q4 | -2.27 Billion KRW | -1914.28% |
| 2023 FY | 963.76 Million KRW | -85.02% |
| 2023 Q3 | -113.04 Million KRW | -108.22% |
| 2023 Q2 | 1.37 Billion KRW | -30.45% |
| 2023 Q1 | 1.97 Billion KRW | 16.89% |
| 2022 Q2 | 3.21 Billion KRW | 786.64% |
| 2022 FY | 6.43 Billion KRW | 209.4% |
| 2022 Q1 | 362.57 Million KRW | 104.52% |
| 2022 Q4 | 1.69 Billion KRW | 78.91% |
| 2022 Q3 | 945.89 Million KRW | -70.58% |
| 2021 Q1 | 706.84 Million KRW | 107.79% |
| 2021 Q2 | 1.06 Billion KRW | 50.93% |
| 2021 Q4 | -8.01 Billion KRW | -2333.17% |
| 2021 Q3 | 358.83 Million KRW | -66.37% |
| 2021 FY | -5.88 Billion KRW | 79.7% |
| 2020 FY | -28.96 Billion KRW | -102.63% |
| 2020 Q3 | -4.58 Billion KRW | 59.29% |
| 2020 Q4 | -9.07 Billion KRW | -97.86% |
| 2020 Q2 | -11.26 Billion KRW | -178.36% |
| 2020 Q1 | -4.04 Billion KRW | 48.45% |
| 2019 Q4 | -7.84 Billion KRW | -1301.82% |
| 2019 FY | -14.29 Billion KRW | -389.54% |
| 2019 Q3 | -559.83 Million KRW | 89.0% |
| 2019 Q2 | -5.09 Billion KRW | -545.16% |
| 2019 Q1 | -789.13 Million KRW | -147.29% |
| 2018 Q3 | 401.62 Million KRW | -69.3% |
| 2018 FY | 4.93 Billion KRW | -33.94% |
| 2018 Q1 | 1.55 Billion KRW | -18.07% |
| 2018 Q2 | 1.3 Billion KRW | -16.06% |
| 2018 Q4 | 1.66 Billion KRW | 315.47% |
| 2017 FY | 7.47 Billion KRW | -25.7% |
| 2017 Q2 | 3.47 Billion KRW | 233.77% |
| 2017 Q3 | 1.06 Billion KRW | -69.41% |
| 2017 Q1 | 1.03 Billion KRW | -39.05% |
| 2017 Q4 | 1.9 Billion KRW | 79.21% |
| 2016 Q1 | 2.39 Billion KRW | 175.63% |
| 2016 Q4 | 1.7 Billion KRW | -20.54% |
| 2016 Q3 | 2.14 Billion KRW | -39.28% |
| 2016 Q2 | 3.53 Billion KRW | 47.9% |
| 2016 FY | 10.05 Billion KRW | 507.15% |
| 2015 Q3 | 2.29 Billion KRW | 338.75% |
| 2015 Q1 | -641.34 Million KRW | -142.01% |
| 2015 Q4 | -3.16 Billion KRW | -237.92% |
| 2015 Q2 | -959.91 Million KRW | -49.67% |
| 2015 FY | -2.47 Billion KRW | -166.3% |
| 2014 Q3 | 878.44 Million KRW | 20.23% |
| 2014 Q2 | 730.66 Million KRW | 23.76% |
| 2014 Q4 | 1.52 Billion KRW | 73.78% |
| 2014 Q1 | 590.36 Million KRW | 7321.6% |
| 2014 FY | 3.72 Billion KRW | -9.24% |
| 2013 Q3 | 972.42 Million KRW | -54.07% |
| 2013 FY | 4.1 Billion KRW | 210.22% |
| 2013 Q2 | 2.11 Billion KRW | 106.73% |
| 2013 Q4 | -8.17 Million KRW | -100.84% |
| 2013 Q1 | 1.02 Billion KRW | 313.01% |
| 2012 Q1 | 2.4 Billion KRW | 0.0% |
| 2012 FY | -3.72 Billion KRW | -134.61% |
| 2012 Q2 | -4.23 Billion KRW | -275.91% |
| 2012 Q3 | -1.19 Billion KRW | 71.82% |
| 2012 Q4 | -480.76 Million KRW | 59.67% |
| 2011 Q1 | 4.66 Billion KRW | 0.0% |
| 2011 Q3 | 2.38 Billion KRW | -36.19% |
| 2011 FY | 10.76 Billion KRW | 17.78% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 Q2 | 3.74 Billion KRW | -19.82% |
| 2010 Q1 | 1.71 Billion KRW | 0.0% |
| 2010 Q3 | 1.56 Billion KRW | -58.52% |
| 2010 FY | 9.13 Billion KRW | 35.04% |
| 2010 Q4 | - KRW | -100.0% |
| 2010 Q2 | 3.76 Billion KRW | 119.06% |
| 2009 Q3 | 1.73 Billion KRW | -4.91% |
| 2009 Q4 | - KRW | -100.0% |
| 2009 FY | 6.76 Billion KRW | -14.11% |
| 2009 Q1 | 1.92 Billion KRW | -29.1% |
| 2009 Q2 | 1.82 Billion KRW | -5.26% |
| 2008 Q3 | -1.3 Billion KRW | -142.17% |
| 2008 Q4 | 2.71 Billion KRW | 308.14% |
| 2008 Q2 | 3.09 Billion KRW | 0.0% |
| 2008 FY | 7.87 Billion KRW | -19.38% |
| 2007 FY | 9.77 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 364.53 Million KRW | -164.381% |
| Dong-A Socio Holdings Co., Ltd. | 76.88 Billion KRW | 98.746% |
| Ildong Holdings Co., Ltd. | -79.56 Billion KRW | 101.211% |
| HANDOK Inc. | 12.57 Billion KRW | 92.338% |
| Kukje Pharma Co., Ltd. | -1.98 Billion KRW | 148.451% |
| Yuhan Corporation | 74.56 Billion KRW | 98.707% |
| Dong-A ST Co., Ltd. | 11.17 Billion KRW | 91.378% |
| SAMSUNG PHARM. Co., LTD. | -18.04 Billion KRW | 105.342% |
| Hanmi Pharm. Co., Ltd. | 224.88 Billion KRW | 99.571% |
| Hanall Biopharma Co.,Ltd | 3.05 Billion KRW | 68.464% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | 93.284% |
| Dong Sung Bio Pharm.Co.,Ltd. | 596.4 Million KRW | -61.596% |
| Hana Pharm Co., Ltd. | 27.03 Billion KRW | 96.435% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -164.381% |
| Ilsung Pharmaceuticals Co., Ltd. | -7.75 Billion KRW | 112.426% |
| REYON Pharmaceutical Co., Ltd. | 4.03 Billion KRW | 76.107% |
| Aprogen pharmaceuticals,Inc. | -69.95 Billion KRW | 101.378% |
| JW Holdings Corporation | 143.66 Billion KRW | 99.329% |
| Ildong Pharmaceutical Co., Ltd. | -53.41 Billion KRW | 101.804% |
| Chong Kun Dang Pharmaceutical Corp. | 246.59 Billion KRW | 99.609% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 99.039% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 102.034% |
| Hyundai Pharmaceutical Co., Ltd. | 6.92 Billion KRW | 86.087% |
| Samil Pharmaceutical Co.,Ltd | 6.47 Billion KRW | 85.106% |
| Jeil Pharmaceutical Co.,Ltd | 8.73 Billion KRW | 88.962% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -164.381% |
| Kwang Dong Pharmaceutical Co., Ltd. | 48.76 Billion KRW | 98.024% |
| Daewoong pharmaceutical Co.,Ltd | 133.4 Billion KRW | 99.278% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 99.039% |
| Yuhan Corporation | 74.56 Billion KRW | 98.707% |
| Jeil Pharma Holdings Inc | 20.92 Billion KRW | 95.393% |
| Yungjin Pharm. Co., Ltd. | 3.11 Billion KRW | 69.084% |
| Suheung Co., Ltd. | 42.99 Billion KRW | 97.758% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 99.039% |
| Samjin Pharmaceuticals Co., Ltd. | 20.48 Billion KRW | 95.295% |
| Korea United Pharm Inc. | 54.94 Billion KRW | 98.246% |
| CKD Bio Corp. | -20.15 Billion KRW | 104.782% |
| Daewon Pharmaceutical Co., Ltd. | 32.23 Billion KRW | 97.01% |
| Dongwha Pharm.Co.,Ltd | 25.3 Billion KRW | 96.191% |
| Whan In Pharm Co.,Ltd. | 32.52 Billion KRW | 97.037% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 102.034% |
| Chong Kun Dang Holdings Corp. | 33.14 Billion KRW | 97.092% |
| Boryung Corporation | 68.26 Billion KRW | 98.588% |
| Bukwang Pharmaceutical Co., Ltd. | -37.49 Billion KRW | 102.57% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | 93.284% |
| JW Lifescience Corporation | 32.09 Billion KRW | 96.997% |